• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Thermo Fisher sees better days ahead

Thermo Fisher sees better days ahead

July 28, 2009 By MassDevice staff

Thermo Fisher Scientific Inc. took it on the chin again during the second quarter, as profits dropped by about 16 percent compared to the same period last year.

But the Waltham, Mass.-based laboratory instruments maker still increased its revenue guidance for the year, citing signs of better days ahead. Overall, the company is expecting revenues in the range of $9.8 billion to $10.1 billion in 2009.

Those estimates fall short of 2008 by about 4 percent to 7 percent, but they paint a far rosier picture than last quarter’s forecast, which called for annual sales in the range of $9.6 billion to $9.9 billion. Company officials credited increased sales from its recent Biolab acquisition and a more favorable climate for foreign exchange for the optimism.

“This leads us to believe that the worst is behind us and that the rest of 2009 will show gradual improvement,” CEO Marjin Dekkers said in a conference call with investors.

Overall, Thermo Fisher posted net income of $207 million, on about $2.5 billion in sales, compared to $246 million on $2.7 billion during the same period last year.

For the year, Thermo Fisher profits are about 25 percent off of last year’s marks.

The company’s analytic technologies business, which makes a wide range of instruments, software, services, bioscience reagents and diagnostic assays for the life sciences industry, was once again the hardest hit, dropping 13 percent compared to last year’s second quarter. The laboratory products and services division fared a bit better, off by only about 3 percent from the same period in 2008.

Despite the drop-off, company officials cited pockets of bright spots, including an unexpected bump from the worldwide Swine Flu pandemic.

“The H1N1 flu virus has been good to us, with our microbiology and healthcare catalog businesses benefiting from sales of test kits in the quarter,” Dekkers told analysts.

The company plans to be aggressive on the acquisitions trail, particularly targeting firms akin to Australia’s Biolab, which Thermo Fisher bought for $120 million in April.

Despite the 2009 slump, Thermo Fisher appears to be well-poised for some shopping in the next six months. The company increased its cash flow by about $350 million during the quarter, bringing total cash and equivalents to $1.4 billion (up 16 percent from the same period last year).

The company has $4.4 billion in total current assets, compared to $4.3 billion from the same period last year.

Filed Under: Business/Financial News, Lab Instruments & Supplies

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy